[go: up one dir, main page]

NO20054411L - Terapeutiske midler omfattende et anti-angiogent middel i kombinasjon med en SRC-inhibitor og deres terapeutiske anvendelse - Google Patents

Terapeutiske midler omfattende et anti-angiogent middel i kombinasjon med en SRC-inhibitor og deres terapeutiske anvendelse

Info

Publication number
NO20054411L
NO20054411L NO20054411A NO20054411A NO20054411L NO 20054411 L NO20054411 L NO 20054411L NO 20054411 A NO20054411 A NO 20054411A NO 20054411 A NO20054411 A NO 20054411A NO 20054411 L NO20054411 L NO 20054411L
Authority
NO
Norway
Prior art keywords
combination
angiogenic agent
therapeutic
src inhibitor
therapeutic agents
Prior art date
Application number
NO20054411A
Other languages
English (en)
Other versions
NO20054411D0 (no
Inventor
Jon Owen Curwen
Stephen Robert Wedge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20054411D0 publication Critical patent/NO20054411D0/no
Publication of NO20054411L publication Critical patent/NO20054411L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Oppfinnelsen angår anvendelse av et antiangiogent middel i kombinasjon med en inhibitor for Src-familien av ikke-reseptor-tyrosinkinaser for fremstilling av et medikament for anvendelse for hovedsakelig normotensiv behandling av et varmblodig pattedyr så som et menneske for en sykdomstilstand forbundet med angiogenese, hvor Src-kinase-inhibitoren blir administrert i en mengde effektiv til i det vesentlige å motvirke hypertensjon fremkalt av det anti-angiogene midlet.
NO20054411A 2003-05-07 2005-09-23 Terapeutiske midler omfattende et anti-angiogent middel i kombinasjon med en SRC-inhibitor og deres terapeutiske anvendelse NO20054411L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0310401.5A GB0310401D0 (en) 2003-05-07 2003-05-07 Therapeutic agent
PCT/GB2004/001939 WO2004098604A1 (en) 2003-05-07 2004-05-04 Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use

Publications (2)

Publication Number Publication Date
NO20054411D0 NO20054411D0 (no) 2005-09-23
NO20054411L true NO20054411L (no) 2005-11-30

Family

ID=9957542

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054411A NO20054411L (no) 2003-05-07 2005-09-23 Terapeutiske midler omfattende et anti-angiogent middel i kombinasjon med en SRC-inhibitor og deres terapeutiske anvendelse

Country Status (14)

Country Link
US (2) US20060223815A1 (no)
EP (1) EP1620104A1 (no)
JP (1) JP2006525304A (no)
KR (1) KR20060009893A (no)
CN (1) CN100418531C (no)
AU (1) AU2004237132B2 (no)
BR (1) BRPI0409742A (no)
CA (1) CA2519930A1 (no)
GB (1) GB0310401D0 (no)
MX (1) MXPA05011858A (no)
NO (1) NO20054411L (no)
NZ (1) NZ542348A (no)
WO (1) WO2004098604A1 (no)
ZA (1) ZA200508858B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
NZ539408A (en) * 2002-11-04 2007-09-28 Astrazeneca Ab Quinazoline derivatives as SRC tyrosine kinase inhibitors for treating solid tumours
GB0226434D0 (en) * 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
EP1713484A2 (en) 2004-01-23 2006-10-25 Amgen Inc. Compounds and methods of use
EP1711495A2 (en) 2004-01-23 2006-10-18 Amgen Inc. Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
GB0406446D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
MXPA06010755A (es) * 2004-03-23 2006-12-15 Astrazeneca Ab Terapia de combinacion.
GB0412074D0 (en) 2004-05-29 2004-06-30 Astrazeneca Ab Combination product
MX2007006230A (es) 2004-11-30 2007-07-25 Amgen Inc Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer.
GB0427697D0 (en) * 2004-12-17 2005-01-19 Astrazeneca Ab Chemical process
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
EP1901754A2 (en) * 2005-07-06 2008-03-26 AstraZeneca AB Combination therapy of cancer with azd2171 and gemcitabine
CA2620436A1 (en) * 2005-08-26 2007-03-01 Antisoma Plc Combinations comprising dmxaa for the treatment of cancer
JP2009520787A (ja) * 2005-12-22 2009-05-28 アストラゼネカ アクチボラグ Ａｚｄ２１７１およびペメトレキセドの組み合わせ
CA2703257C (en) * 2007-10-29 2013-02-19 Amgen Inc. Benzomorpholine derivatives and methods of use
WO2009068906A2 (en) * 2007-11-26 2009-06-04 Astrazeneca Ab Combinations comprising zd4054 and a src family kinase inhibitor 172
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
JP6426195B2 (ja) * 2013-11-01 2018-11-21 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物の結晶形態及びその使用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
SK288365B6 (sk) * 1999-02-10 2016-07-01 Astrazeneca Ab Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
UA73993C2 (uk) * 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
KR100821446B1 (ko) * 2000-08-21 2008-04-10 아스트라제네카 아베 퀴나졸린 유도체
WO2002092579A1 (en) * 2001-05-14 2002-11-21 Astrazeneca Ab 4-anilinoquinazoline derivatives
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
EP1534287A1 (en) * 2002-08-09 2005-06-01 Astrazeneca AB Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
GB0226434D0 (en) * 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
ATE506062T1 (de) * 2003-02-13 2011-05-15 Astrazeneca Ab Kombinationstherapie von zd6474 mit 5-fu oder/und cpt-11
GB0316127D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
GB0316123D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
WO2005004870A1 (en) * 2003-07-10 2005-01-20 Astrazeneca Ab Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
MXPA06010755A (es) * 2004-03-23 2006-12-15 Astrazeneca Ab Terapia de combinacion.
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
GB0412074D0 (en) * 2004-05-29 2004-06-30 Astrazeneca Ab Combination product
EP1804802A2 (en) * 2004-09-27 2007-07-11 AstraZeneca AB Combination comprising zd6474 and an imatinib
US20080015205A1 (en) * 2004-09-27 2008-01-17 Wedge Stephen R Cancer Combination Therapy Comprising Azd2171 and Imatinib
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
JP4834985B2 (ja) * 2004-12-10 2011-12-14 日産自動車株式会社 組電池の容量調整装置

Also Published As

Publication number Publication date
NO20054411D0 (no) 2005-09-23
US20100029673A1 (en) 2010-02-04
NZ542348A (en) 2009-01-31
AU2004237132B2 (en) 2007-10-18
CN100418531C (zh) 2008-09-17
MXPA05011858A (es) 2006-02-17
ZA200508858B (en) 2007-03-28
EP1620104A1 (en) 2006-02-01
AU2004237132A1 (en) 2004-11-18
KR20060009893A (ko) 2006-02-01
WO2004098604A1 (en) 2004-11-18
GB0310401D0 (en) 2003-06-11
JP2006525304A (ja) 2006-11-09
CN1784232A (zh) 2006-06-07
CA2519930A1 (en) 2004-11-18
BRPI0409742A (pt) 2006-05-09
US20060223815A1 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
NO20054411L (no) Terapeutiske midler omfattende et anti-angiogent middel i kombinasjon med en SRC-inhibitor og deres terapeutiske anvendelse
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
NO20074446L (no) DR5-antistoffer og anvendelser derav
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
NO20074431L (no) Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer
UY28958A1 (es) Nuevos derivados de piridazin-3(2h)-ona
NO20065727L (no) Pyrrolinhibitorer av erk-proteinkinase, syntese derav og deres mellomprodukter
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
MY139689A (en) Imidazotriazines as protein kinase inhibitors
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
NO20061327L (no) Kinazolinderivater
NO20084435L (no) C-MET proteinkinaseinhibitorer
DE602005020611D1 (de) Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
NO20092130L (no) Tricykliske heteroarylforbindelser anvendelige som inhibitorer of januskinase
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
WO2007087068A3 (en) Inhibitors of tyrosine kinases and uses thereof
NO20061323L (no) Kinazolinderivater
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
NO20066081L (no) Kinazolinderivater som erbB-reseptortyrosinkinaser
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20060328L (no) Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser
NO20073878L (no) Kinazolinderivater som tyrosin kinase inhibitorer
NO20065079L (no) Materialer og metoder for behandling av koaguleringssykdommer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application